| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Kroll Mark W serves as a Director at HAE and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 1 buy and 35 sells.
Historically, Kroll Mark W's trades have earned a below-average insider score of 36/100 across 6 rated trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -27.2%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2018 | Director | Sell | 7,097 | $64.34 | $456,620.98 | -22.7% | ||
| Jan 2, 2018 | HAE Haemonetics Corp | Director | Sale+OE | 7,118 | $63.00 | $448,434.00 | -21.0% | |
| May 15, 2017 | HAE Haemonetics Corp | Director | Sale+OE | 8,580 | $41.49 | $355,982.32 | -27.7% | |
| Feb 27, 2015 | HAE Haemonetics Corp | Director | Sale+OE | 11,328 | $44.80 | $507,483.07 | -47.8% |